skip to main content
DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Methods and kits for predicting a response to an erythropoietic agent

Abstract

Methods for predicting a response to an erythropoietic agent in a subject include providing a biological sample from the subject, and determining an amount in the sample of at least one peptide selected from the group consisting of SEQ ID NOS: 1-17. If there is a measurable difference in the amount of the at least one peptide in the sample, when compared to a control level of the same peptide, the subject is then predicted to have a good response or a poor response to the erythropoietic agent. Kits for predicting a response to an erythropoietic agent are further provided and include one or more antibodies, or fragments thereof, that specifically recognize a peptide of SEQ ID NOS: 1-17.

Inventors:
; ; ;
Issue Date:
Research Org.:
University of Louisville Research Foundation, Inc., Louisville, KY (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1184560
Patent Number(s):
9,057,731
Application Number:
13/167,478
Assignee:
University of Louisville Research Foundation, Inc. (Louisville, KY)
DOE Contract Number:  
FG02-05ER64060
Resource Type:
Patent
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; 59 BASIC BIOLOGICAL SCIENCES

Citation Formats

Merchant, Michael L., Klein, Jon B., Brier, Michael E., and Gaweda, Adam E. Methods and kits for predicting a response to an erythropoietic agent. United States: N. p., 2015. Web.
Merchant, Michael L., Klein, Jon B., Brier, Michael E., & Gaweda, Adam E. Methods and kits for predicting a response to an erythropoietic agent. United States.
Merchant, Michael L., Klein, Jon B., Brier, Michael E., and Gaweda, Adam E. Tue . "Methods and kits for predicting a response to an erythropoietic agent". United States. https://www.osti.gov/servlets/purl/1184560.
@article{osti_1184560,
title = {Methods and kits for predicting a response to an erythropoietic agent},
author = {Merchant, Michael L. and Klein, Jon B. and Brier, Michael E. and Gaweda, Adam E.},
abstractNote = {Methods for predicting a response to an erythropoietic agent in a subject include providing a biological sample from the subject, and determining an amount in the sample of at least one peptide selected from the group consisting of SEQ ID NOS: 1-17. If there is a measurable difference in the amount of the at least one peptide in the sample, when compared to a control level of the same peptide, the subject is then predicted to have a good response or a poor response to the erythropoietic agent. Kits for predicting a response to an erythropoietic agent are further provided and include one or more antibodies, or fragments thereof, that specifically recognize a peptide of SEQ ID NOS: 1-17.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2015},
month = {6}
}

Patent:

Save / Share:

Works referenced in this record:

Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option
journal, December 2006

  • Cornes, Paul; Coiffier, Bertrand; Zambrowski, Jean-Jacques
  • Current Medical Research and Opinion, Vol. 23, Issue 2, p. 357-368
  • DOI: 10.1185/030079906X167282

Anemia of inflammation: the cytokine-hepcidin link
journal, May 2004


Specificity of interactions of galectin-3 with Chrp, a cysteine- and histidine-rich cytoplasmic protein
journal, February 2003


Oncostatin M Regulates the Synthesis and Turnover of gp130, Leukemia Inhibitory Factor Receptor α, and Oncostatin M Receptor β by Distinct Mechanisms
journal, October 2001

  • Blanchard, Frédéric; Wang, Yanping; Kinzie, Erin
  • Journal of Biological Chemistry, Vol. 276, Issue 50, p. 47038-47045
  • DOI: 10.1074/jbc.M107971200

Inflammatory Markers and Platelet Aggregation Tests as Predictors of Hemoglobin and Endogenous Erythropoietin Levels in Hemodialysis Patients
journal, January 2002

  • Borawski, Jacek; Pawlak, Krystyna; Myśliwiec, Michał
  • Nephron, Vol. 91, Issue 4, p. 671-681
  • DOI: 10.1159/000065030

Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas
journal, July 2008

  • Chen, D. R.; Chu, C-Y.; Chen, C-Y.
  • The Journal of Pathology, Vol. 215, Issue 3, p. 290-299
  • DOI: 10.1002/path.2361

Model Predictive Control of Erythropoietin Administration in the Anemia of ESRD
journal, January 2008

  • Gaweda, Adam E.; Jacobs, Alfred A.; Aronoff, George R.
  • American Journal of Kidney Diseases, Vol. 51, Issue 1, p. 71-79
  • DOI: 10.1053/j.ajkd.2007.10.003

Role of cytokines in the response to erythropoietin in hemodialysis patients
journal, October 1998


Soluble Erythropoietin Receptor Contributes to Erythropoietin Resistance in End-Stage Renal Disease
journal, February 2010


Precision proteomics: The case for high resolution and high mass accuracy
journal, September 2008

  • Mann, M.; Kelleher, N. L.
  • Proceedings of the National Academy of Sciences, Vol. 105, Issue 47, p. 18132-18138
  • DOI: 10.1073/pnas.0800788105

Cellular Cholesterol Depletion Triggers Shedding of the Human Interleukin-6 Receptor by ADAM10 and ADAM17 (TACE)
journal, June 2003

  • Matthews, Vance; Schuster, Björn; Schütze, Stefan
  • Journal of Biological Chemistry, Vol. 278, Issue 40, p. 38829-38839
  • DOI: 10.1074/jbc.M210584200

Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis
journal, March 2006

  • Menon, Madhu P.; Karur, Vinit; Bogacheva, Olga
  • Journal of Clinical Investigation, Vol. 116, Issue 3, p. 683-694
  • DOI: 10.1172/JCI25227

Interaction of a novel cysteine and histidine-rich cytoplasmic protein with galectin-3 in a carbohydrate-independent manner
journal, March 2000


Urinary Peptidome May Predict Renal Function Decline in Type 1 Diabetes and Microalbuminuria
journal, July 2009

  • Merchant, M. L.; Perkins, B. A.; Boratyn, G. M.
  • Journal of the American Society of Nephrology, Vol. 20, Issue 9, p. 2065-2074
  • DOI: 10.1681/ASN.2008121233

Proteomic analysis of renal calculi indicates an important role for inflammatory processes in calcium stone formation
journal, October 2008

  • Merchant, Michael L.; Cummins, Timothy D.; Wilkey, Daniel W.
  • American Journal of Physiology-Renal Physiology, Vol. 295, Issue 4, p. F1254-F1258
  • DOI: 10.1152/ajprenal.00134.2008

Dual Oncostatin M (OSM) Receptors: Cloning And Characterization Of An Alternative Signaling Subunit Conferring OSM-Specific Receptor Activation
journal, December 1996

  • Mosley, Bruce; De Imus, Cyr; Friend, Della
  • Journal of Biological Chemistry, Vol. 271, Issue 51, p. 32635-32643
  • DOI: 10.1074/jbc.271.51.32635

IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
journal, May 2004

  • Nemeth, Elizabeta; Rivera, Seth; Gabayan, Victoria
  • Journal of Clinical Investigation, Vol. 113, Issue 9, p. 1271-1276
  • DOI: 10.1172/JCI200420945

Targeted disruption of oncostatin M receptor results in altered hematopoiesis
journal, November 2003


Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure
journal, January 2008

  • van der Putten, Karien; Braam, Branko; Jie, Kim E.
  • Nature Clinical Practice Nephrology, Vol. 4, Issue 1, p. 47-57
  • DOI: 10.1038/ncpneph0655

Hypoxia-inducible factor 1α is up-regulated by oncostatin M and participates in oncostatin M signaling
journal, March 2009

  • Vollmer, Stefan; Kappler, Valérie; Kaczor, Jakub
  • Hepatology, Vol. 50, Issue 1, p. 253-260
  • DOI: 10.1002/hep.22928

Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes
journal, September 2008

  • Szczech, Lynda A.; Barnhart, Huiman X.; Inrig, Jula K.
  • Kidney International, Vol. 74, Issue 6, p. 791-798
  • DOI: 10.1038/ki.2008.295

Epoetin requirements predict mortality in hemodialysis patients
journal, November 2004